Stealth BioTherapeutics Inc. - Company Profile
Powered by 
All the data and insights you need on Stealth BioTherapeutics Inc. in one report.
$295
- Save hours of research time and resources with
our up-to-date Stealth BioTherapeutics Inc. Strategy Report
- Understand Stealth BioTherapeutics Inc. position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Stealth BioTherapeutics Inc (Stealth BioTherapeutics), formerly Stealth Peptides International Inc, is an early stage biotechnology company. It discovers, develops, and commercializes novel therapies for diseases and disorders associated with mitochondrial dysfunction. The company is investigating elamipretide, a peptide compound that penetrates into cell membranes, for the treatment of primary mitochondrial myopathy, barth syndrome, duchenne cardiomyopathy, and dry age-related macular degeneration. It is also evaluating SBT-272, a phase I candidate, for the treatment of rare neurodegenerative diseases. Stealth BioTherapeutics is headquartered in Grand Cayman, Cayman Islands.
Headquarters
United States of America
Address
Suite 201, 123 Highland Ave, Needham, Massachusetts, 02494
Website
www.stealthbt.com
Telephone
1 617 6006888
Industry
Pharmaceuticals and Healthcare
Stealth BioTherapeutics Inc. premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline Product |
| Elamipretide for the Treatment of- |
| -Primary Mitochondrial Myopathy |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In May, the company entered into a licensing agreement with Pharmanovia to commercialize Elamipretide for the treatment of barth syndrome in europe and key global territories. |
| 2022 | Regulatory Approval | In November, the company's pipeline product SBT-272 Granted Orphan Drug Designation for Treatment of ALS. |
| 2022 | Contracts/Agreements | In August, the company agreed to merge with Morningside. |
Competitor Comparison
| Key Parameters | Stealth BioTherapeutics Inc. | Regeneron Pharmaceuticals Inc | Astellas Pharma Inc | Ionis Pharmaceuticals Inc | Apellis Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Japan | United States of America | United States of America |
| City | Needham | Tarrytown | Chuo-Ku | Carlsbad | Waltham |
| State/Province | Massachusetts | New York | Tokyo | California | Massachusetts |
| No. of Employees | - | 13,450 | 14,484 | 927 | 702 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Reenie McCarthy | Director; Chief Executive Officer | Executive Board | 2015 | - |
| Henry Hess | Chief Legal Counsel | Senior Management | - | - |
| Jim Carr | Chief Clinical Development Officer | Senior Management | 2017 | - |
| Brian Blakey | Chief Business Officer | Senior Management | 2014 | - |
| Brian Saxton | Vice President - Quality Assurance | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward